It targets BCMA on multiple myeloma (MM) cells and was approved by the FDA on March 26, 2021 for relapsed or refractory MM after four or more lines of systemic therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody based on the KarMMa study. The gene discussed is CD38; the disease is Miyoshi myopathy.